PRODUCT – Page 3

Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

2 months ago talkbio0Tagged Acelyrin, Acquisition, all-stock, Alumis, Biological Factors, Concentra Biosciences, Immunology, Merger, Transaction

Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction

BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease

2 months ago talkbio0Tagged BioCity, Biopharma, Diabetic Nephropathy, EDNRA gene, ETA, Phase 2 trial, Proteinuria, SC0062

SC0062, endothelin receptor type A (ETA) antagonist, diabetic kidney disease (DKD), proteinuria reduction, phase 2 trial, BioCity Biopharma

Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans

2 months ago talkbio0Tagged Acelyrin, Alumis, biopharmaceutical industry, Concentra Biosciences, Disruption, M&A, Merger, Unsolicited Adverse Event

Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

2 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up

2 months ago talkbio0Tagged Adolescent (age group), Approved, Bavarian Nordic, chikungunya vaccine, traveler, United States Food and Drug Administration, Vaccines, Virus-Like Particle, Vimkunya

Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers

AlgoTx’s ATX01 Shows Promise Despite Missing Primary Endpoint in Phase 2 CIPN Trial

2 months ago talkbio0Tagged AlgoTx, ATX01, Effect, non-opioid pain relief, Peripheral neuropathy due to and following antineoplastic therapy, Phase 2 trial, Placebos, topical amitriptyline

AlgoTx, ATX01, chemotherapy-induced peripheral neuropathy (CIPN), Phase 2 trial, placebo effect, non-opioid pain relief, topical amitriptyline

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

2 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

2 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Merck KGaA in Advanced Negotiations to Acquire SpringWorks Therapeutics

2 months ago talkbio0Tagged Acquisition, biopharmaceutical industry, cancer treatments, Does speak, Merck KGaA, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition talks, biopharmaceutical industry, rare diseases, cancer treatments, Ogsiveo

Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership

2 months ago talkbio0Tagged Accord BioPharma, Bio-Thera, Biopharma, Biosimilars, golimumab, Intas, namilumab, Roivant, Sarcoidosis, Pulmonary, Solutions

Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma